47 completed, 17 recruiting, 16 unknown, 15 active not recruiting. 110 Phase 3, 10 Phase 2.
By phase and status
Phase Trials Status Phase 3 110 Completed 47 , Recruiting 17 , Unknown 16 , Active not recruiting 15 , Not yet recruiting 6 , Terminated 6 , Withdrawn 3 Phase 2 10 Completed 4 , Active not recruiting 2 , Recruiting 2 , Terminated 1 , Unknown 1
Follow Fallopian Tube Diseases: new trials by email Literature Review of Fallopian Tube Diseases trials Research Report on Fallopian Tube Diseases
Trials (filtered) newest first · largest first
All 110 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Rina-S, Bevacizumab - Ovarian Cancer Phase 3 Not yet recruiting 602 2026-11-01 2026-10-05 A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer Phase 3 Recruiting 646 2026-10-07 2026-10-30 A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer Phase 3 Not yet recruiting 600 2026-10-01 2026-09-01 Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer Phase 3 Not yet recruiting 600 2026-10-01 2026-09-10 Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer Phase 3 Recruiting 600 2026-09-24 2026-10-16 A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) R-DXd, Bevacizumab - Ovarian Cancer, Ovarian Neoplasms Phase 3 Recruiting 802 2026-09-18 2026-10-29 Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Epithelial Ovarian Cancer Phase 3 Recruiting 950 2026-09-16 2026-10-01 A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer Phase 3 Not yet recruiting 404 2026-07-01 2026-06-29 An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer Phase 3 Recruiting 82 2026-06-26 2026-10-06 A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer Sofetabart Mipitecan, Paclitaxel, Topotecan - Ovarian Neoplasms, Fallopian Tube Neoplasms Phase 3 Recruiting 1630 2025-10-22 2026-10-08 A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan - Epithelial Ovarian Cancer, Fallopian Tube Cancer Phase 3 Recruiting 450 2025-08-04 2026-07-07 Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Ovarian Cancer Phase 3 Recruiting 500 2025-07-09 2026-10-30 PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer PARP inhibitor + Bevacizumab, PARP inhibitor - Ovarian Cancer, Fallopian Tube Cancers Phase 2 / Phase 3 Recruiting 120 2025-07-01 2026-03-16 A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist - Ovarian Cancer, Fallopian Tube Cancer Phase 3 Recruiting 770 2025-04-09 2026-10-13 Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer IBI354, paclitaxel/Gemcitabine/Liposomal doxorubicin - Ovarian, Primary Peritoneal Phase 3 Active not recruiting 450 2025-03-17 2026-09-09 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer Phase 3 Active not recruiting 584 2025-02-07 2026-09-28 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer JSKN003, Doxorubicin, Paclitaxel - Ovarian Cancer, Primary Peritoneal Phase 3 Not yet recruiting 430 2025-01-15 2024-12-31 Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients Aprepitant Injection - Gynecological Tumor, Ovarian Cancer Phase 3 Completed 143 2024-05-31 2025-12-04 Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer Cisplatin, No treatment - Stage III Ovarian Cancer, Stage IV Ovarian Cancer Phase 3 Recruiting 220 2024-03-08 2026-04-16 A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer R-DXd, Paclitaxel, Topotecan - Solid Cancer Phase 2 / Phase 3 Recruiting 860 2024-02-27 2026-10-26
Showing 20 of 110. Sign in to see all of them.
Narrower conditions Fallopian Tube Neoplasms (110) · Ovarian Neoplasms (87) · Carcinoma, Ovarian Epithelial (47) · Peritoneal Neoplasms (13) · Brenner Tumor (7) · Endometrial Neoplasms (6) · Neoplasms (5) · Uterine Cervical Neoplasms (5) · Recurrence (4) · Breast Neoplasms (3) · Pain (3) · Prostatic Neoplasms (3) · Vaginal Neoplasms (3) · Vulvar Neoplasms (3) · Adenocarcinoma, Clear Cell (2)
Broader conditions Adnexal Diseases (110) · Female Urogenital Diseases (110) · Female Urogenital Diseases and Pregnancy Complications (110) · Genital Diseases (110) · Neoplasms by Site (110) · Urogenital Diseases (110) · Urogenital Neoplasms (110) · Genital Diseases, Female (109) · Genital Neoplasms, Female (108) · Endocrine System Diseases (107) · Gonadal Disorders (107) · Ovarian Diseases (106) · Neoplasms (105) · Endocrine Gland Neoplasms (104)
Interventions Paclitaxel (51) · Carboplatin (36) · Bevacizumab (26) · liposomal doxorubicin (20) · Topotecan (15) · Gemcitabine (12) · Taxes (11) · Cisplatin (6) · Doxorubicin (6) · Drug Therapy (6) · Disulfides (5) · Docetaxel (5) · Immunoglobulin G (5) · mirvetuximab soravtansine (5) · rucaparib (5)
Sponsors National Cancer Institute (NCI) (8) · Merck Sharp & Dohme LLC (5) · AGO Study Group (4) · Medical Research Council (4) · pharmaand GmbH (4) · Alliance for Clinical Trials in Oncology (3) · Amgen (3) · Eli Lilly and Company (3) · GOG Foundation (3) · Genmab (3) · Gynecologic Oncology Group (3) · Shanghai Gynecologic Oncology Group (3) · AbbVie (2) · AstraZeneca (2) · Daiichi Sankyo (2)
Countries United States (59) · Canada (33) · Italy (33) · South Korea (32) · Australia (29) · Spain (29) · United Kingdom (28) · China (26) · Germany (26) · Belgium (25) · France (24) · Japan (21) · Israel (19) · Poland (19) · Czechia (16)
Top investigators Ignace B. Vergote, MD, PhD (3) · Hee Seung Kim, MD/PhD (2) · Shuzhong Cui, M.D (2) · Zhongqiu Lin, M.D (2) · Adrian Jubb, MBChB, PhD, FRCPath (1) · Amanda N Fader (1) · Amreen Husain, MD (1) · Andreas Obermair, MD FRANZCOG CGO (1) · Andreas du Bois, MD, PhD (1)
Results publications PMID 37185961 , PMID 37407274 , PMID 21941283 , PMID 35170751 , PMID 12829663 , PMID 12860964 , PMID 14656276 , PMID 16239238 , PMID 16882940 , PMID 17704410 , PMID 18336399 , PMID 18768432 , PMID 19224848 , PMID 19767092 , PMID 20733132 , PMID 20818904 , PMID 20850296 , PMID 20888993 , PMID 21410972 , PMID 22204724 , PMID 22204725 , PMID 22480131 , PMID 22539562 , PMID 22987083 , PMID 23219660 , PMID 23850170 , PMID 23948349 , PMID 24318743 , PMID 24356636 , PMID 24366937 , PMID 25070546 , PMID 25225436 , PMID 25434635 , PMID 25827292 , PMID 25964591 , PMID 26244011 , PMID 26271155 , PMID 26487588 , PMID 26588236 , PMID 26933849 , PMID 27020837 , PMID 27025186 , PMID 27029706 , PMID 27394382 , PMID 27769273 , PMID 27997900 , PMID 28438473 , PMID 28916367 , PMID 29267856 , PMID 29324537
NIH funding U10CA180868 (10) , U10CA027469 (7) , 2025 (4) , 2009 (2) , 2016 (2) , 2017 (2) , 2019 (2) , 2023 (2) , U10CA101165 (2) , 2008 (1) , 2018 (1) , P30CA043703 (1) , U10CA032102 (1) , U10CA037404 (1) , U10CA180830 (1)